{"count":2329,"next":"https://api-test.medunigraz.at/v1/research/project/?format=json&limit=20&offset=1860&ordering=-end_planned","previous":"https://api-test.medunigraz.at/v1/research/project/?format=json&limit=20&offset=1820&ordering=-end_planned","results":[{"id":1719,"title":{"de":"GATiB II - Koordination","en":"GATiB II - Coordination"},"short":"GATIB_II_Koordination","url":null,"abstract":{"de":"Biobanken für die biomedizinische Forschung sind Sammlungen von biologischem Material (Gewebe, Zellen, Blut, Körperflüssigkeiten, inklusive der daraus isolierten Biomoleküle) und den zugehörigen Daten über den Probendonor. Diese biologischen Materialien enthalten wertvolle Informationen über genetische und nicht-genetische Krankheitsursachen und über Faktoren, die den Krankheitsverlauf beeinflussen. Aufgrund dieser Relevanz sehen mehrere internationale Organisationen biologische Materialien als essentielle Rohmaterialien, um den Fortschritt in Biotechnologie und Gesundheitswesen voranzutreiben.\r\nGATiB basiert auf einem einzigartigen Pathologiearchiv an der Medizinischen Universität Graz und enthält über 3 Millionen Proben von 800.000 Patienten, die nahezu alle Krankheiten einer mitteleuropäischen Bevölkerung in der natürlichen Häufigkeit abbilden.\r\n\r\nGEN-AU I förderte die Umwandlung dieses Archivs in eine Biobank (GATiB)\r\nSchwerpunkt in GEN-AU II war die Erhöhung des wissenschaftlichen Wertes und des Nutzens der 3 Millionen archivierter Proben durch halbautomatische Annotation der Proben mit medizinischen Daten und Patienten-Überlebensdaten.\r\nIn GEN-AU III wird GATiB II den Schwerpunkt auf die prospektive Sammlung von Proben und Daten, sowie internationale Integration legen. Es ist eine Probensammlung geplant, deren Design spezifisch die Forschung an metabolischen Erkrankungen unterstützt - eine anerkannte Stärke der Forschung an der Medizinischen Universität und den anderen Grazer Universitäten. Dies erfordert die Entwicklung verbesserter Gefrierkonservierungs- und Gefrierlagermethoden für Gewebe um das Potenzial moderner metabolomischer Analysemethoden optimal ausnützen zu können.","en":"Biobanken für die biomedizinische Forschung sind Sammlungen von biologischem Material (Gewebe, Zellen, Blut, Körperflüssigkeiten, inklusive der daraus isolierten Biomoleküle) und den zugehörigen Daten über den Probendonor. Diese biologischen Materialien enthalten wertvolle Informationen über genetische und nicht-genetische Krankheitsursachen und über Faktoren, die den Krankheitsverlauf beeinflussen. Aufgrund dieser Relevanz sehen mehrere internationale Organisationen biologische Materialien als essentielle Rohmaterialien, um den Fortschritt in Biotechnologie und Gesundheitswesen voranzutreiben.\r\nGATiB basiert auf einem einzigartigen Pathologiearchiv an der Medizinischen Universität Graz und enthält über 3 Millionen Proben von 800.000 Patienten, die nahezu alle Krankheiten einer mitteleuropäischen Bevölkerung in der natürlichen Häufigkeit abbilden.\r\n\r\nGEN-AU I förderte die Umwandlung dieses Archivs in eine Biobank (GATiB)\r\nSchwerpunkt in GEN-AU II war die Erhöhung des wissenschaftlichen Wertes und des Nutzens der 3 Millionen archivierter Proben durch halbautomatische Annotation der Proben mit medizinischen Daten und Patienten-Überlebensdaten.\r\nIn GEN-AU III wird GATiB II den Schwerpunkt auf die prospektive Sammlung von Proben und Daten, sowie internationale Integration legen. Es ist eine Probensammlung geplant, deren Design spezifisch die Forschung an metabolischen Erkrankungen unterstützt - eine anerkannte Stärke der Forschung an der Medizinischen Universität und den anderen Grazer Universitäten. Dies erfordert die Entwicklung verbesserter Gefrierkonservierungs- und Gefrierlagermethoden für Gewebe um das Potenzial moderner metabolomischer Analysemethoden optimal ausnützen zu können."},"begin_planned":"2009-05-01T02:00:00+02:00","begin_effective":"2009-10-01T02:00:00+02:00","end_planned":"2012-04-30T02:00:00+02:00","end_effective":"2012-09-30T02:00:00+02:00","assignment":"2009-01-15T10:26:42+01:00","program":73,"subprogram":null,"organization":14020,"category":10,"type":10,"partner_function":3,"manager":51663,"contact":51663,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[152],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1719-50828-12","1719-51663-10"]},{"id":1720,"title":{"de":"GATIB II, Genome Austria Tissue Bank (GEN-AU III)","en":"GATIB II, Genome Austria Tissue Bank (GEN-AU III)"},"short":"GATIB II_GENAU_III_Trauner","url":null,"abstract":{"de":"Biobanken für die biomedizinische Forschung sind Sammlungen von biologischem Material (Gewebe, Zellen, Blut, Körperflüssigkeiten, inklusive der daraus isolierten Biomoleküle) und den zugehörigen Daten über den Probendonor. Diese biologischen Materialien enthalten wertvolle Informationen über genetische und nicht-genetische Krankheitsursachen und über Faktoren, die den Krankheitsverlauf beeinflussen. Aufgrund dieser Relevanz sehen mehrere internationale Organisationen biologische Materialien als essentielle Rohmaterialien, um den Fortschritt in Biotechnologie und Gesundheitswesen voranzutreiben.\r\nGATiB basiert auf einem einzigartigen Pathologiearchiv an der Medizinischen Universität Graz und enthält über 3 Millionen Proben von 800.000 Patienten, die nahezu alle Krankheiten einer mitteleuropäischen Bevölkerung in der natürlichen Häufigkeit abbilden.\r\n\r\nGEN-AU I förderte die Umwandlung dieses Archivs in eine Biobank (GATiB)\r\nSchwerpunkt in GEN-AU II war die Erhöhung des wissenschaftlichen Wertes und des Nutzens der 3 Millionen archivierter Proben durch halbautomatische Annotation der Proben mit medizinischen Daten und Patienten-Überlebensdaten.\r\nIn GEN-AU III wird GATiB II den Schwerpunkt auf die prospektive Sammlung von Proben und Daten, sowie internationale Integration legen. Es ist eine Probensammlung geplant, deren Design spezifisch die Forschung an metabolischen Erkrankungen unterstützt - eine anerkannte Stärke der Forschung an der Medizinischen Universität und den anderen Grazer Universitäten. Dies erfordert die Entwicklung verbesserter Gefrierkonservierungs- und Gefrierlagermethoden für Gewebe um das Potenzial moderner metabolomischer Analysemethoden optimal ausnützen zu können.","en":"Biobanken für die biomedizinische Forschung sind Sammlungen von biologischem Material (Gewebe, Zellen, Blut, Körperflüssigkeiten, inklusive der daraus isolierten Biomoleküle) und den zugehörigen Daten über den Probendonor. Diese biologischen Materialien enthalten wertvolle Informationen über genetische und nicht-genetische Krankheitsursachen und über Faktoren, die den Krankheitsverlauf beeinflussen. Aufgrund dieser Relevanz sehen mehrere internationale Organisationen biologische Materialien als essentielle Rohmaterialien, um den Fortschritt in Biotechnologie und Gesundheitswesen voranzutreiben.\r\nGATiB basiert auf einem einzigartigen Pathologiearchiv an der Medizinischen Universität Graz und enthält über 3 Millionen Proben von 800.000 Patienten, die nahezu alle Krankheiten einer mitteleuropäischen Bevölkerung in der natürlichen Häufigkeit abbilden.\r\n\r\nGEN-AU I förderte die Umwandlung dieses Archivs in eine Biobank (GATiB)\r\nSchwerpunkt in GEN-AU II war die Erhöhung des wissenschaftlichen Wertes und des Nutzens der 3 Millionen archivierter Proben durch halbautomatische Annotation der Proben mit medizinischen Daten und Patienten-Überlebensdaten.\r\nIn GEN-AU III wird GATiB II den Schwerpunkt auf die prospektive Sammlung von Proben und Daten, sowie internationale Integration legen. Es ist eine Probensammlung geplant, deren Design spezifisch die Forschung an metabolischen Erkrankungen unterstützt - eine anerkannte Stärke der Forschung an der Medizinischen Universität und den anderen Grazer Universitäten. Dies erfordert die Entwicklung verbesserter Gefrierkonservierungs- und Gefrierlagermethoden für Gewebe um das Potenzial moderner metabolomischer Analysemethoden optimal ausnützen zu können."},"begin_planned":"2009-05-01T02:00:00+02:00","begin_effective":"2009-10-01T02:00:00+02:00","end_planned":"2012-04-30T02:00:00+02:00","end_effective":"2012-06-30T02:00:00+02:00","assignment":"2009-01-15T10:32:33+01:00","program":73,"subprogram":null,"organization":14081,"category":10,"type":10,"partner_function":2,"manager":null,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[152],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":[]},{"id":2780,"title":{"de":"Gelotophobie - Die „Angst vor dem Lachen anderer“ - Studie zur Erforschung der zu Grunde liegenden emotionalen Prozesse in spontaner Interaktion.","en":"Gelotophobia - A biopsychological approach"},"short":"Gelotophobie","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2012-02-01T01:00:00+01:00","begin_effective":"2012-02-01T01:00:00+01:00","end_planned":"2012-04-30T02:00:00+02:00","end_effective":"2012-04-30T02:00:00+02:00","assignment":"2012-02-06T18:26:26+01:00","program":null,"subprogram":null,"organization":14010,"category":10,"type":10,"partner_function":3,"manager":64295,"contact":64295,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[135],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["2780-64295-10"]},{"id":2602,"title":{"de":"Verlust des RAF Kinase Inhibitor Proteins bei der akuten myeloischen Leukämie","en":"Loss of RAF Kinase Inhibitor Protein in acute myeloid leukemia"},"short":"RKIP Verlust bei AML","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2011-10-15T02:00:00+02:00","begin_effective":"2011-10-15T02:00:00+02:00","end_planned":"2012-04-15T02:00:00+02:00","end_effective":"2012-10-15T02:00:00+02:00","assignment":"2011-10-03T13:18:57+02:00","program":null,"subprogram":null,"organization":14082,"category":10,"type":10,"partner_function":4,"manager":57402,"contact":57402,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[423],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["2602-57402-10"]},{"id":2940,"title":{"de":"Ein Vergleich häufig verwendeter Opiate und Hypnotika hinsichtlich ihres Einflusses auf die gastrointestinale Motilität","en":"a comparison of frequently used opioids and hypnotics regarding their influence on gastrointestinal motility"},"short":null,"url":null,"abstract":{"de":null,"en":null},"begin_planned":"2011-10-01T02:00:00+02:00","begin_effective":"2012-04-01T02:00:00+02:00","end_planned":"2012-04-01T02:00:00+02:00","end_effective":"2014-01-31T01:00:00+01:00","assignment":"2012-08-08T15:49:29+02:00","program":null,"subprogram":null,"organization":14070,"category":10,"type":10,"partner_function":4,"manager":71082,"contact":71082,"status":2,"research":3,"grant":10,"event":null,"study":null,"language":null,"funders":[135],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["2940-71082-10"]},{"id":2758,"title":{"de":"Body Composition and Performance: Relatives Körpergewicht österreichischer Athleten","en":"Body Composition and Performance"},"short":"Body Composition","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2012-01-01T01:00:00+01:00","begin_effective":"2012-01-01T01:00:00+01:00","end_planned":"2012-03-31T02:00:00+02:00","end_effective":"2012-03-31T02:00:00+02:00","assignment":"2012-01-19T16:37:18+01:00","program":90,"subprogram":null,"organization":14011,"category":10,"type":10,"partner_function":4,"manager":null,"contact":null,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[1326],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":[]},{"id":3002,"title":{"de":"Dkk-1 im peripheren Blut zur Unterscheidung von intrazerebraler Blutung und ischämischem Insult","en":"Dkk-1 in peripheral blood to discriminate between intracerebral hemorrhaghe and ischemic stroke"},"short":null,"url":null,"abstract":{"de":null,"en":null},"begin_planned":"2012-10-01T02:00:00+02:00","begin_effective":"2012-11-01T01:00:00+01:00","end_planned":"2012-03-31T02:00:00+02:00","end_effective":"2014-06-30T02:00:00+02:00","assignment":"2012-10-16T15:26:36+02:00","program":null,"subprogram":null,"organization":14051,"category":10,"type":10,"partner_function":4,"manager":53287,"contact":53287,"status":2,"research":4,"grant":10,"event":null,"study":null,"language":null,"funders":[135],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["3002-53287-10"]},{"id":2204,"title":{"de":"Funktionelle Effekte des Multikinase-Hemmers Sunitinib auf Myokard","en":"Functional effects on myocardium and influence on cardiac microRNA expression induced by the cancer therapeutic agent sunitinib"},"short":"Functional effects sunitinib","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2010-04-01T02:00:00+02:00","begin_effective":"2010-04-01T02:00:00+02:00","end_planned":"2012-03-31T02:00:00+02:00","end_effective":"2013-03-31T01:00:00+01:00","assignment":"2010-05-14T12:06:21+02:00","program":null,"subprogram":null,"organization":14085,"category":10,"type":10,"partner_function":4,"manager":null,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[140],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":[]},{"id":2520,"title":{"de":"CORA-BGF 2011 Untersuchung der positiven Auswirkungen erhöhter Gravitationsbelastung auf die Kreislaufbelastbarkeit","en":"CORA-BGF 2011 Untersuchung der positiven Auswirkungen erhöhter Gravitationsbelastung auf die Kreislaufbelastbarkeit"},"short":"CORA GBF","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2011-07-01T02:00:00+02:00","begin_effective":"2011-07-01T02:00:00+02:00","end_planned":"2012-03-30T02:00:00+02:00","end_effective":"2012-03-30T02:00:00+02:00","assignment":"2011-07-05T14:52:27+02:00","program":null,"subprogram":null,"organization":14010,"category":10,"type":10,"partner_function":4,"manager":57932,"contact":57932,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[135],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["2520-57932-10"]},{"id":1991,"title":{"de":"Proteomic characterization of mitochondrial ion channels","en":"Proteomic characterization of mitochondrial ion channels"},"short":"mitochondrial ion channels","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2010-01-01T01:00:00+01:00","begin_effective":"2010-01-01T01:00:00+01:00","end_planned":"2012-03-13T01:00:00+01:00","end_effective":"2012-03-13T01:00:00+01:00","assignment":"2009-11-25T16:00:48+01:00","program":69,"subprogram":null,"organization":14013,"category":10,"type":10,"partner_function":4,"manager":null,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"J2968-B19","ethics_committee":null,"edudract_number":null,"persons":[]},{"id":2436,"title":{"de":"Translational Research Pilotprojekt zur ABCSG Studie: Primärtumoroperation in synchronisiert metastasiertem invasiven Brusktrebs, multizentrische prospektive randomisierte Studie zur Evaluierung des Nutzens der Lokaltherapie","en":"Pilot Translational Research Project to the ABSCG study: Primary Operation in Synchronous metastasized InVasivE breast cancer (POSYTIVE), a multicenter prospective randomized study to evaluate the use of local therapy"},"short":"Trans- POSYTIVE","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2010-03-01T01:00:00+01:00","begin_effective":"2010-03-01T01:00:00+01:00","end_planned":"2012-03-01T01:00:00+01:00","end_effective":"2014-12-31T01:00:00+01:00","assignment":"2011-03-03T11:02:36+01:00","program":81,"subprogram":null,"organization":14085,"category":10,"type":10,"partner_function":4,"manager":59188,"contact":59188,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[52],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["2436-80692-12","2436-50539-12","2436-59188-10"]},{"id":2659,"title":{"de":"Doktoratskolleg \"Metabolische und kardiovaskuläre Erkrankungen\" ","en":"Doktoratskolleg: \"Metabolic and cardiovascular disease\""},"short":"DK_METABOL_DISORDERS","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2010-07-01T02:00:00+02:00","end_planned":"2012-02-28T01:00:00+01:00","end_effective":"2014-06-30T02:00:00+02:00","assignment":"2010-10-20T13:09:58+02:00","program":66,"subprogram":null,"organization":14021,"category":10,"type":10,"partner_function":2,"manager":null,"contact":null,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"W1226","ethics_committee":null,"edudract_number":null,"persons":[]},{"id":2654,"title":{"de":"Doktoratskolleg \"Metabolische und kardiovaskuläre Erkrankungen\" ","en":"Doktoratskolleg \"Metabolic disorders and cellular dysfunction\" "},"short":"DK_METABOL_DISORDERS","url":null,"abstract":{"de":"Proteomic investigation of lipotoxicity in tumor-associated cachexia\r\nObjective: To elucidate possible causes and effects of tumor-induced lipotoxicity on the proteome level.\r\nCachexia is commonly recognized as progressive weight loss with depletion of host reserves of adipose tissue and skeletal muscle and associated with cancers of gastrointestinal tract and lung. Survival of cancer patients is directly related to weight loss. The reduction of food intake alone is unable to explain the metabolic changes seen in cachexia. Moreover, loss of muscle and adipose tissue precedes the fall in food intake. The causes and mechanisms responsible for tumor-associated cachexia remain to be unravelled. Preliminary data generated in Gerald Hoefler´s laboratory demonstrate an involvement of adipose triglyceride lipase (ATGL) in the development of cachexia. While implantation of Lewis lung carcinoma cells into wild-type mice resulted in a vast reduction of gastrognemious muscle and white adipose tissue and a minor reduction in heart weight, none of these effects were seen in ATGL-ko mice.\r\nTissues from cachexia mouse models will be obtained from G. Hoefler. Proteomes from gastrognemious muscle, adipose tissues, liver, heart and spleen of wild-type and ATGL-ko mice with and without transplanted tumor will be profiled with respect to protein abundance by differential gelelectrophoresis (DIGE) and/or isotope labeling, liquid chromatography and mass spectrometry (LC-MS). Phosphoproteomics of selected cellular fractions will be performed using immobilized metal affinity chromatography (IMAC, TiO2) for phosphopeptide enrichment, isotopic labeling for quantification, LC-MS with phospho-group neutral loss scanning and database search for phospho-group modifications. Differences in lipase and esterase activities will be assessed by activity-based proteomics employing suitable probes (developed by the applicant) and by standard proteomic techniques.\r\n\r\nRegulatory and compensatory mechanisms of lipolytic pathways\r\nBackground: While the lipolytic proteome of mouse adipose tissue has been identified (3), many of the underlying regulatory processes remain unknown. Therefore, regulatory and compensatory mechanisms of lipolytic pathways as well as changes in the overall proteome will be determined upon shut down of individual pathways (e.g. in hormone sensitive lipase (HSL)- and ATGL-deficient mice). The phenotypes of the respective mouse models differ greatly with regard to body weight, lipid accumulation, fertility and organ specific defects. Thus, large effects are expected to be observed on the protein level in adipose and other tissues as well as in macrophages and foam cells.\r\nObjective: To elucidate the underlying regulatory, compensatory and pathogenic mechanisms of lipid accumulation on the proteome level.\r\nProteins interacting with recently identified lipases, as well as lipid droplet-associated proteins, which might regulate substrate accessibility, will be isolated from tissue fractions or cell lines, identified by LC-MS and analyzed for the presence of isomers and post-translational modifications, especially phosphorylation. Related tissue/cell fractions or immunoprecipitations will be profiled with respect to protein abundance by DIGE and/or isotopic labelling and LC-MS. Selected proteins will be confirmed by Western blotting. Phosphoproteomics and activity-based proteomics will be applied as described in Project 1.\r\n","en":null},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2010-07-01T02:00:00+02:00","end_planned":"2012-02-28T01:00:00+01:00","end_effective":"2014-06-30T02:00:00+02:00","assignment":"2010-10-20T13:09:58+02:00","program":66,"subprogram":null,"organization":28394,"category":10,"type":10,"partner_function":2,"manager":58794,"contact":58794,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"W1226","ethics_committee":null,"edudract_number":null,"persons":["2654-58794-10"]},{"id":2661,"title":{"de":"Doktoratskolleg \"Metabolische und Kardiovaskuläre Erkrankungen\"","en":"Doktoratskolleg: \"Metabolic and cardiovascular disease\""},"short":"DK_METABOL_DISORDERS","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2010-07-01T02:00:00+02:00","end_planned":"2012-02-28T01:00:00+01:00","end_effective":"2014-06-30T02:00:00+02:00","assignment":"2010-10-20T13:09:58+02:00","program":66,"subprogram":null,"organization":14020,"category":10,"type":10,"partner_function":2,"manager":51663,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"W1226","ethics_committee":null,"edudract_number":null,"persons":["2661-51663-10"]},{"id":1820,"title":{"de":"NANO-AS: Nano-Tox-Verlängerung","en":"NANO-AS: Nano-Tox-Verlängerung"},"short":"NANO-AS","url":null,"abstract":{"de":"The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity","en":"The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity"},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2009-03-01T01:00:00+01:00","end_planned":"2012-02-28T01:00:00+01:00","end_effective":"2012-02-28T01:00:00+01:00","assignment":"2009-05-18T12:36:34+02:00","program":null,"subprogram":"Nano-Health","organization":28394,"category":10,"type":10,"partner_function":2,"manager":53900,"contact":53900,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[416],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1820-53900-10"]},{"id":2656,"title":{"de":"Doktoratskolleg \"Metabolische und kardiovaskuläre Erkrankungen\" ","en":"Doktoratskolleg: \"Metabolic and cardiovascular disease\""},"short":"DK_METABOL_DISORDERS","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2010-07-01T02:00:00+02:00","end_planned":"2012-02-28T01:00:00+01:00","end_effective":"2014-06-30T02:00:00+02:00","assignment":"2010-10-20T13:09:58+02:00","program":66,"subprogram":null,"organization":14013,"category":10,"type":10,"partner_function":2,"manager":51904,"contact":51904,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"W1226","ethics_committee":null,"edudract_number":null,"persons":["2656-51904-10"]},{"id":2027,"title":{"de":"Effects of 25-OH-vitamin D supplementation in coronary artery disease patients with postprandial hyperglycemia and vitamin D deficiency on endothelial function and insulin sensitivity","en":"Effects of 25-OH-vitamin D supplementation in coronary artery disease patients with postprandial hyperglycemia and vitamin D deficiency on endothelial function and insulin sensitivity"},"short":"VITAMIN D_CORONARY ARTERY","url":null,"abstract":{"de":null,"en":null},"begin_planned":"2010-03-01T01:00:00+01:00","begin_effective":"2010-03-01T01:00:00+01:00","end_planned":"2012-02-28T01:00:00+01:00","end_effective":"2013-02-28T01:00:00+01:00","assignment":"2009-12-22T13:08:42+01:00","program":79,"subprogram":null,"organization":14080,"category":10,"type":10,"partner_function":4,"manager":50838,"contact":50838,"status":2,"research":2,"grant":10,"event":null,"study":null,"language":null,"funders":[12],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["2027-50838-10"]},{"id":1819,"title":{"de":"Nano-Health: 4D Molecular Imaging of human Stem Cells in vivo","en":"Nano-Health: 4D Molecular Imaging of human Stem Cells in vivo"},"short":"Nano-Health: 4D Imaging of Stem Cells","url":null,"abstract":{"de":"The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity","en":"The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity"},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2009-03-01T01:00:00+01:00","end_planned":"2012-02-28T01:00:00+01:00","end_effective":"2012-02-28T01:00:00+01:00","assignment":"2009-05-18T11:50:29+02:00","program":null,"subprogram":"Nano-Health","organization":14082,"category":10,"type":10,"partner_function":2,"manager":null,"contact":null,"status":2,"research":3,"grant":10,"event":null,"study":null,"language":null,"funders":[416],"funder_projectcode":null,"ethics_committee":null,"edudract_number":null,"persons":["1819-50747-12"]},{"id":2663,"title":{"de":"Doktoratskolleg \"Metabolische und Kardiovaskuläre Erkrankungen\"","en":"Doktoratskolleg: \"Metabolic and cardiovascular disease\""},"short":"DK_METABOL_DISORDERS","url":null,"abstract":{"de":"Projekt 1 erarbeit die subuellulären Mechanismen getriggerter Arrhythmien unter besonderer Berücksichtigung eines gestörten Funktion des Ryanodin-Rezeptors des sarkoplasmatischen Retikulums.\r\n\r\nProjekt 2 untersucht den Einfluss von milder Hypothermie auf Hämodynamik, zelluläre und subzelluläre Funktion im Schockmodell und Sepsismodell.","en":null},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2010-07-01T02:00:00+02:00","end_planned":"2012-02-28T01:00:00+01:00","end_effective":"2014-06-30T02:00:00+02:00","assignment":"2009-12-18T01:00:00+01:00","program":66,"subprogram":null,"organization":14083,"category":10,"type":10,"partner_function":2,"manager":null,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"W1226","ethics_committee":null,"edudract_number":null,"persons":[]},{"id":2658,"title":{"de":"Doktoratskolleg \"Metabolische und kardiovaskuläre Erkrankungen\" ","en":"Doktoratskolleg: \"Metabolic and cardiovascular disease\""},"short":"DK_METABOL_DISORDERS","url":null,"abstract":{"de":null,"en":"Identifying the molecular and regulatory mechanisms of HDL metabolism at the BBB will help to uncover the protective role of HDL against lipid-related neurodegenerative diseases such as Alzheimer’s disease.\r\nDuring the first funding period of the DK-Plus, students in U. Panzenboeck’s group will characterize phospholipid transfer protein function at the BBB to test the hypothesis if PLTP expression in cerebrovascular endothelial cells (EC) can be modulated and is involved in HDL remodelling and in lipid transport between the brain and the circulation. In a second show case the student will investigate the capacity of HDL particles to mediate/facilitate bidirectional oxysterol transport across the BBB and will aim to identify oxysterol transporting proteins in brain capillary EC. \r\n"},"begin_planned":"2009-03-01T01:00:00+01:00","begin_effective":"2010-07-01T02:00:00+02:00","end_planned":"2012-02-28T01:00:00+01:00","end_effective":"2014-06-30T02:00:00+02:00","assignment":"2010-10-20T13:09:58+02:00","program":66,"subprogram":null,"organization":14014,"category":10,"type":10,"partner_function":2,"manager":null,"contact":null,"status":2,"research":1,"grant":10,"event":null,"study":null,"language":null,"funders":[9],"funder_projectcode":"W1226","ethics_committee":null,"edudract_number":null,"persons":[]}]}